4
Changes in Ownership
Sionna Therapeutics, Inc. Filed Acc 0001704336-25-000006
President & CEO sold 25,200 shares at an average $31.28 ($788,153)
- President & CEO acquired 25,200 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Cloonan Michael · President & CEO
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-10-15 | Exercise or conversion : show line 1 in the form 10b5-1 | +14,775 | $6.11 | $90,275 | 562,118 | D |
| 2025-10-15 | Sale : show line 2 in the form 10b5-1 | −14,775 | $31.11 | $459,662 | 547,343 | D |
| 2025-10-16 | Exercise or conversion : show line 3 in the form 10b5-1 | +10,225 | $6.11 | $62,475 | 557,568 | D |
| 2025-10-16 | Sale : show line 4 in the form 10b5-1 | −10,225 | $31.46 | $321,691 | 547,343 | D |
| 2025-10-16 | Exercise or conversion : show line 5 in the form 10b5-1 | +200 | $6.11 | $1,222 | 547,543 | D |
| 2025-10-16 | Sale : show line 6 in the form 10b5-1 | −200 | $34.00 | $6,800 | 547,343 | D |
| Open-market sales · 25,200 sh · avg $31.28 · $788,153 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-10-15 | Exercise or conversion : show line 7 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −14,775 | 163,367 | D |
| 2025-10-16 | Exercise or conversion : show line 8 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −10,225 | 153,142 | D |
| 2025-10-16 | Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −200 | 152,942 | D |
Loading xslF345X05/edgardoc.xml…